Additional Supporting Information may be found in the online version of this article.

hep26597-sup-0001-suppfig1.tif4300KSupporting Fig. 1. Overactivation of the TGF-β pathway in HCC cells that show a mesenchymal-like phenotype. Correlation with higher production of TGF-β. (Complement to Fig. 1).
hep26597-sup-0002-suppfig2.tif1253KSupporting Fig. 2. CXCL12 increases the migratory capacity of SNU449 cells, whereas has no effect on HepG2 cells. (Complement to Fig. 2).
hep26597-sup-0003-suppfig3.tif4767KSupporting Fig. 3. Stable silencing of TGFBRI in PLC/PRF/5 induces reorganization of the cytoskeleton and attenuates expression and asymmetric distribution of CXCR4. (Complement to Fig. 3).
hep26597-sup-0004-suppfig4.tif951KSupporting Fig. 4. Effect of pharmacological inhibition of TGFBR1 kinase in the mesenchymal HCC cell lines. (Complement to Fig. 4).
hep26597-sup-0005-suppfig5.tif4171KSupporting Fig. 5. DEN treatment was used to induce HCC in mice. (Complement to Fig. 5).
hep26597-sup-0006-suppfig6.tif12580KSupporting Fig. 6. Higher expression of both TGFB1 and CXCR4 in tumor tissues correlates with differentiation stages III/IV (less differentiated phenotype) and a cirrhotic background in HCC patients. (Complement to Fig. 6).
hep26597-sup-0007-suppinfo1.doc51KSupporting Information
hep26597-sup-0008-suppinfo2.doc29KSupporting Information
hep26597-sup-0009-supptab1.doc37KSupplementary Table 1. Molecular characteristics of the human HCC cell lines used in this study.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.